RU2011111640A - Антитела против cd5 - Google Patents

Антитела против cd5 Download PDF

Info

Publication number
RU2011111640A
RU2011111640A RU2011111640/10A RU2011111640A RU2011111640A RU 2011111640 A RU2011111640 A RU 2011111640A RU 2011111640/10 A RU2011111640/10 A RU 2011111640/10A RU 2011111640 A RU2011111640 A RU 2011111640A RU 2011111640 A RU2011111640 A RU 2011111640A
Authority
RU
Russia
Prior art keywords
antibody
antibodies
composition according
antibody composition
composition
Prior art date
Application number
RU2011111640/10A
Other languages
English (en)
Russian (ru)
Inventor
Джозефин Л.К. КЛИТГОР (DK)
Джозефин Л.К. КЛИТГОР
Чарльз ПАЙК (DK)
Чарльз ПАЙК
Миккель Ваннахль ПЕДЕРСЕН (DK)
Миккель Ваннахль ПЕДЕРСЕН
Клаус КОФОД (DK)
Клаус КОФОД
Original Assignee
Симфоген А/С (Dk)
Симфоген А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Симфоген А/С (Dk), Симфоген А/С filed Critical Симфоген А/С (Dk)
Publication of RU2011111640A publication Critical patent/RU2011111640A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2011111640/10A 2008-08-29 2009-08-28 Антитела против cd5 RU2011111640A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200801191 2008-08-29
DKPA200801191 2008-08-29
US9370008P 2008-09-02 2008-09-02
US61/093,700 2008-09-02

Publications (1)

Publication Number Publication Date
RU2011111640A true RU2011111640A (ru) 2012-10-10

Family

ID=40677719

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011111640/10A RU2011111640A (ru) 2008-08-29 2009-08-28 Антитела против cd5

Country Status (15)

Country Link
US (1) US20110250203A1 (cg-RX-API-DMAC10.html)
EP (1) EP2328932A1 (cg-RX-API-DMAC10.html)
JP (1) JP2012500815A (cg-RX-API-DMAC10.html)
KR (1) KR20110050541A (cg-RX-API-DMAC10.html)
CN (1) CN102137873A (cg-RX-API-DMAC10.html)
AU (1) AU2009287164A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0917148A2 (cg-RX-API-DMAC10.html)
CA (1) CA2735279A1 (cg-RX-API-DMAC10.html)
IL (1) IL209975A0 (cg-RX-API-DMAC10.html)
MX (1) MX2011000970A (cg-RX-API-DMAC10.html)
NZ (1) NZ591153A (cg-RX-API-DMAC10.html)
RU (1) RU2011111640A (cg-RX-API-DMAC10.html)
TW (1) TW201011045A (cg-RX-API-DMAC10.html)
WO (1) WO2010022737A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201100300B (cg-RX-API-DMAC10.html)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103490A2 (en) 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
US20140079722A1 (en) * 2011-03-09 2014-03-20 Centrose, Llc Extracellular targeted drug conjugates
WO2013023162A2 (en) * 2011-08-10 2013-02-14 Genus Oncology, Llc Anti-muc1 antibodies for cancer diagnostics
MX350335B (es) 2011-08-17 2017-09-04 Univ California Anticuerpos que enlazan alfa-v beta-8 integrina.
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN102786595B (zh) * 2012-08-03 2014-04-23 无锡傲锐东源生物科技有限公司 抗cd5蛋白单克隆抗体及其用途
WO2014100740A1 (en) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
SG11201504920SA (en) * 2012-12-27 2015-07-30 Sanofi Sa Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
SG10201806481XA (en) * 2014-02-19 2018-09-27 Emergent Biosolutions Canada Inc Marburg monoclonal antibodies
HK1245171A1 (zh) 2014-11-26 2018-08-24 Xencor, Inc. 结合cd3和cd38的异二聚体抗体
JP6696982B2 (ja) 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
MA41962A (fr) 2015-04-23 2018-02-28 Baylor College Medicine Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
WO2017214285A1 (en) * 2016-06-07 2017-12-14 Eynav Klechevsky Detection of cd5 and methods and compositions for modulating cd5
RU2019102008A (ru) 2016-06-28 2020-07-28 Ксенкор, Инк. Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
SI4339615T1 (sl) * 2016-09-16 2026-01-30 Shanghai Henlius Biotech, Inc. Protitelesa anti-pd-1 za uporabo pri zdravljenju raka
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
AU2018374283B2 (en) 2017-11-29 2025-09-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD5+ cells
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
WO2019204507A1 (en) 2018-04-18 2019-10-24 Biomadison, Inc. Methods for determining vaccine potency
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
AU2019404302A1 (en) 2018-12-19 2021-08-05 The Trustees Of The University Of Pennsylvania Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias
CA3131096A1 (en) 2019-04-05 2020-10-08 Chi-Huey Wong Sialidase-resistant saccharide and method of making and using the same
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CA3182526A1 (en) 2020-05-08 2021-11-11 Academia Sinica Chimeric influenza vaccines
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2021231982A1 (en) * 2020-05-14 2021-11-18 City Of Hope Smc1a antibodies and uses thereof
EP4149632A1 (en) 2020-05-14 2023-03-22 Xencor, Inc. Heterodimeric antibodies that bind msln and cd3
EP3915641A1 (en) * 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
JP2023538108A (ja) * 2020-08-21 2023-09-06 シティ・オブ・ホープ 抗ｃｄ５抗体組成物及びその使用
EP4211245A1 (en) 2020-09-14 2023-07-19 Vor Biopharma Inc. Compositions and methods for cd5 modification
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii
CN116801905A (zh) * 2020-12-17 2023-09-22 先声再明医药有限公司 Cd5抗体及其应用
WO2022152185A1 (zh) * 2021-01-12 2022-07-21 南京驯鹿医疗技术有限公司 靶向cd5的全人源抗体
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
WO2022221837A2 (en) 2021-04-12 2022-10-20 Academia Sinica Improved coronavirus vaccine
EP4332118A1 (en) * 2021-04-29 2024-03-06 Korea Research Institute of Bioscience and Biotechnology Novel anti-cd5 chimeric antigen receptor and immune cell expressing same
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
CN113105547B (zh) * 2021-05-18 2022-04-08 福州迈新生物技术开发有限公司 抗cd5蛋白单克隆抗体及其细胞株、制备方法和应用
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US12077597B2 (en) 2021-11-24 2024-09-03 International-Drug-Development-Biotech Anti-CD5 antibodies and methods of use thereof
US20230279080A1 (en) * 2021-12-27 2023-09-07 Academia Sinica Antibody specific to spike protein of sars-cov-2 and uses thereof
WO2024039683A1 (en) * 2022-08-15 2024-02-22 Myeloid Therapeutics, Inc. Compositions and methods for conditioning patients for cell therapy
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
NZ825394A (en) 2023-04-08 2026-03-27 Rock Biomedical Inc Methods and compositions for dendritic cell targeting nano-delivery
CA3268566A1 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
CN121175414A (zh) 2023-05-17 2025-12-19 磐石医药生技股份有限公司 Mgat1缺乏细胞及其用途
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024258967A1 (en) * 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025220805A1 (ko) * 2024-04-18 2025-10-23 주식회사 큐로셀 신규한 항-cd5 키메릭 항원 수용체 및 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4312916C2 (de) * 1993-04-14 1995-03-23 Fresenius Ag Arzneimittel zur Behandlung von Immunreaktionen

Also Published As

Publication number Publication date
BRPI0917148A2 (pt) 2015-12-01
JP2012500815A (ja) 2012-01-12
KR20110050541A (ko) 2011-05-13
US20110250203A1 (en) 2011-10-13
ZA201100300B (en) 2012-01-25
EP2328932A1 (en) 2011-06-08
CN102137873A (zh) 2011-07-27
AU2009287164A1 (en) 2010-03-04
WO2010022737A1 (en) 2010-03-04
CA2735279A1 (en) 2010-03-04
TW201011045A (en) 2010-03-16
IL209975A0 (en) 2011-02-28
NZ591153A (en) 2012-12-21
MX2011000970A (es) 2011-03-15

Similar Documents

Publication Publication Date Title
Santich et al. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies
US12060418B2 (en) Bispecific IgG antibodies as T cell engagers
JP2012500815A5 (cg-RX-API-DMAC10.html)
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
JP2026069499A (ja) Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用
EP4347655A1 (en) Anti-ccr8 antibodies and uses thereof
JP7773372B2 (ja) 線維芽細胞活性化タンパク質結合物質およびその使用
RU2016151645A (ru) Биспецифические гетеродимерные диантитела и их применение
RU2013157040A (ru) Поливалентная антиген-связывающая fv-молекула
US20140308285A1 (en) Heterodimeric bispecific antibodies
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
RU2014109039A (ru) Биспецифические антигенсвязывающие молекулы
RU2015118180A (ru) Антитела к бета-амилоиду
RU2012128343A (ru) АНТИ-С4.4а АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
JP2016513467A (ja) ヘテロ二量体性二重特異性抗体
RU2012136234A (ru) Антагонистические антитела против рецептора il-7 и способы
RU2014153440A (ru) Антитела против cd26 и их применение
GB2613464A (en) Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
PE20231080A1 (es) Anticuerpos que se unen a cd3 y cd19
RU2013134983A (ru) Рекомбинантные антитела против фактора роста эндотелия сосудов (vegf), полученные посредством мутагенеза вариабельной области
Boje et al. Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
KR20240103034A (ko) Tigit 및 pd-l1에 대한 이중특이적 항체, 그의 의약 조성물, 및 그의 용도
JP2024531149A (ja) 炎症誘発性サイトカイン放出からｔ細胞性腫瘍細胞毒性をデカップリングするタンパク質
CN111662382A (zh) 特异结合cd3的抗体、抗原结合片段和单链抗体可变区片段及其应用
WO2021140222A1 (en) Anti-cd40 antibodies and compositions

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20131127